Overview
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.
Background
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.
Indication
For the treatment of mild to moderate essential or primary hypertension . Effective as most first-line antihypertensives when used as monotherapy .
Associated Conditions
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/04/06 | Phase 1 | Recruiting | |||
2021/12/07 | Phase 4 | Completed | |||
2020/07/21 | Phase 4 | Completed | |||
2020/07/17 | Phase 4 | Recruiting | |||
2020/04/01 | Phase 1 | Terminated | Italo Biaggioni | ||
2019/10/28 | Early Phase 1 | Active, not recruiting | |||
2019/08/08 | Early Phase 1 | Active, not recruiting | |||
2015/02/04 | Not Applicable | Completed | National Research Center for Preventive Medicine | ||
2013/02/15 | Phase 4 | Completed | Spyridon Deftereos | ||
2012/03/30 | Phase 4 | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Moxonidine Hydrochloride Tablets | 国药准字H20020495 | 化学药品 | 片剂 | 6/4/2020 | |
| Moxonidine Hydrochloride Tablets | 国药准字H20041250 | 化学药品 | 片剂 | 8/21/2020 | |
| Moxonidine Hydrochloride Tablets | 国药准字H20030949 | 化学药品 | 片剂 | 6/12/2020 | |
| Moxonidine Hydrochloride Tablets | 国药准字H20000333 | 化学药品 | 片剂 | 12/26/2019 | |
| Moxonidine Hydrochloride Capsules | 国药准字H20040897 | 化学药品 | 胶囊剂 | 4/20/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| MOXOTENS moxonidine 400 microgram tablet blister pack | 300129 | Medicine | A | 7/2/2019 | |
| MOXONIDINE LAPL moxonidine 200 microgram film-coated tablet blister pack | 291315 | Medicine | A | 7/9/2018 | |
| MOXONIDINE GX moxonidine 200 microgram tablet blister pack | 287646 | Medicine | A | 1/25/2018 | |
| MOXONIDINE VIATRIS moxonidine 400 microgram tablet blister pack | 287645 | Medicine | A | 1/25/2018 | |
| MOXONIDINE SCP moxonidine 400 microgram film-coated tablet blister pack | 285635 | Medicine | A | 1/16/2018 | |
| MOXONIDINE GPPL moxonidine 400 microgram tablet blister pack | 300128 | Medicine | A | 7/2/2019 | |
| MOXONIDINE GENPAR moxonidine 400 microgram tablet blister pack | 300133 | Medicine | A | 7/2/2019 | |
| MOXONIDINE GH moxonidine 400 microgram film-coated tablet blister pack | 291317 | Medicine | A | 7/9/2018 | |
| MOXONIDINE SCP moxonidine 200 microgram film-coated tablet blister pack | 285627 | Medicine | A | 1/16/2018 | |
| MOXONIDINE-WGR moxonidine 200 microgram tablet blister pack | 300130 | Medicine | A | 7/2/2019 |